Business
Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022
SAN DIEGO, July 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, July 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the William Blair Biotech Focus Conference 2022. The conference will take place July 12-13, 2022.\n\n \n \n \n \n \n \n\n \nDetails for this event are as follows:\nWilliam Blair Biotech Focus Conference 2022Details: Brian Lian, Ph.D., chief executive officer of Viking, will participate in a fireside chat and Viking management will participate in 1-on-1 meetingsConference Dates: July 12-13, 2022Fireside Chat Timing: Webcast available starting on Monday, July 11, 2022Location: The St. Regis New YorkA webcast of the fireside chat may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts starting on Monday, July 11, 2022.\nAbout Viking Therapeutics, Inc. \nViking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's second clinical candidate is VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company's third clinical can...